Roche Palo Alto LLC

Other

Tobias Gabriel

Nolan James Dewdney

Michael Soth

Nidhi Arora

David Michael Goldstein

Roland Joseph Billedeau

Nancy Elisabeth Krauss

Teresa Alejandra Trejo-Martin

David Bernard Smith

Yan Lou

Counde O'Yang

Wylie Solang Palmer

Taraneh Mirzadegan

Kristen Lynn McCaleb

Joe Timothy Bamberg

Kin-Chun Thomas Luk

Rama K Kondru

Joel McIntosh

This application discloses pyridine and pyrimidine compounds according to formula I wherein R, R, R, R, R, Xand A are as described herein which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of formula I and at least one carrier, diluent or excipient.

Btk protein kinase inhibitors

Compounds of formula I: wherein R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds, pharmaceutical compositions, methods of using the compounds for treatment of p38 MAP kinase-mediated diseases, and methods of using the compounds for treatment of Raf kinase-mediated diseases.

Kinase inhibitors and methods for using the same

Compounds of formula Ia, Ib, Ic, Id, Ie, If, Ig or Ih: wherein X and Y are nitrogen or one of X and Y is nitrogen and the other is CR, and W, D, E, R, R, Rand Rare as defined herein. Also disclosed are methods of making the subject compounds and methods of using the compounds in the treatment of p38 MAP kinase-mediated diseases.

Substituted pyrazolo[3,4-D]pyrimidines as p38 MAP kinase inhibitors

Compounds of formula Ia or Ib: wherein A, W, X, Y, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and methods of using the compounds for treatment of p38 MAP kinase-mediated diseases.

Substituted pyrazolo[3,4-d]pyrimidines as p38 MAP kinase inhibitors

Compounds effective as p38 MAP kinase inhibitors, methods of making the compounds, and methods of using the compounds for treatment of p38 MAP kinase-mediated diseases.

Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors

Compounds of the formula Ia or Ib: wherein X and Y are N or one of X and Y is N and the other is CR, and A, D, E, G, W, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the subject compounds and methods of using the compounds for treatment of p38 MAP kinase-mediated diseases.

Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors

Compounds of formula Ia or Ib: wherein R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and methods of using the compounds for treatment of p38 MAP kinase-mediated diseases.

Compounds of formula Ia or Ib: wherein X and Y are nitrogen or CR, and R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the subject compounds and methods of using the compounds for treatment of p38-mediated diseases.

p38 MAP kinase inhibitors and methods for using the same

Compounds of the formula I: or pharmaceutically acceptable salts, solvates or prodrugs thereof,wherein m, k, B, R, Rand Rare those defined herein, and compositions comprising the same. Also provided are methods for preparing compounds of formula I and using the same in treating p38 mediated disorders in a patient.

Indazole derivatives and methods for using the same

Compounds of the formula I: where A, B, X, Y, Z, k, R, Rand Rare those defined herein, and compositions comprising the same. The present invention also provides methods for preparing compounds of formula I and using the same in treating p38 mediated disorders in a patient.

Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same

Compounds of the formula Ia or Ib: wherein A, B, X, Y, Z, W, k, R, R, R, Rand Rare those defined herein, and compositions comprising the same. The present invention also provides methods for preparing compounds of formula I and using the same in treating p38 mediated disorders in a subject.

Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same

The present invention provides a compound of the Formula: a pharmaceutically acceptable salt, a solvate, or a prodrug thereof, wherein m, n, Ar, R, R, R, R, and Rare those defined herein. The present invention also provides methods for using and preparing compounds of Formula I.

Cathepsin K inhibitors

Compounds of the formula (I) wherein m, n, A, R, R, R, R, Rand Rare as described herein, together with methods for making the compounds and using the compounds for treatment of diseases or conditions mediated by Cathepsin K.

Growing community of inventors

San Francisco, CA, United States of America

Tobias Gabriel